Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited ... Phosphodiesterase type 5; PH: Pulmonary hypertension.

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

Blood levels of two markers may help predict treatment response and outcomes in pulmonary arterial hypertension patients, per ...

CAMPHOR and PAH-SYMPACT are the most reliable QOL tools for PAH, with Grade A ratings for internal reliability. LPHQ and ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among ...

The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg ...

[105] This trial enrolled 405 PAH patients (a majority were WHO functional class II and III) and randomized them to placebo or tadalafil 2.5, 10, 20, or 40 mg daily for 16 weeks. Compared with ...